Ventyx Biosciences (NASDAQ:VTYX) CEO Sells $365,503.40 in Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan sold 47,345 shares of Ventyx Biosciences stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $365,503.40. Following the completion of the transaction, the chief executive officer owned 2,372,863 shares in the company, valued at $18,318,502.36. This represents a 1.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Ventyx Biosciences Price Performance

Shares of NASDAQ VTYX opened at $8.74 on Monday. Ventyx Biosciences, Inc. has a 1-year low of $0.78 and a 1-year high of $10.55. The business has a fifty day moving average price of $7.90 and a 200 day moving average price of $4.52. The stock has a market capitalization of $623.69 million, a P/E ratio of -5.83 and a beta of 1.22.

Ventyx Biosciences (NASDAQ:VTYX) last posted its earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.13. As a group, equities research analysts anticipate that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ventyx Biosciences

Several hedge funds have recently made changes to their positions in VTYX. Affinity Asset Advisors LLC purchased a new position in Ventyx Biosciences during the 2nd quarter worth approximately $9,707,000. Marshall Wace LLP acquired a new stake in shares of Ventyx Biosciences in the second quarter worth $5,129,000. Redmile Group LLC increased its stake in shares of Ventyx Biosciences by 1,164.1% in the first quarter. Redmile Group LLC now owns 1,569,793 shares of the company’s stock worth $1,805,000 after acquiring an additional 1,445,615 shares during the period. Baker BROS. Advisors LP purchased a new position in shares of Ventyx Biosciences during the third quarter worth $3,182,000. Finally, AQR Capital Management LLC lifted its position in Ventyx Biosciences by 925.6% during the first quarter. AQR Capital Management LLC now owns 880,222 shares of the company’s stock valued at $1,012,000 after purchasing an additional 794,401 shares during the period. 97.88% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

VTYX has been the subject of a number of analyst reports. HC Wainwright raised shares of Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 target price for the company in a research report on Wednesday, November 5th. Canaccord Genuity Group increased their price objective on Ventyx Biosciences from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday, November 7th. Wells Fargo & Company raised their price objective on Ventyx Biosciences from $11.00 to $14.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Oppenheimer boosted their target price on Ventyx Biosciences from $9.00 to $14.00 and gave the stock an “outperform” rating in a research note on Monday, October 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Ventyx Biosciences in a research note on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.50.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.